ZNTL
Zentalis Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Zentalis Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Squadron Capital ManagementSquadron | $20.0M | 8.60% | +2.36% | |
| 2 | 5AM Venture Management5AM Venture | $19.1M | 8.23% | 0.00% | |
| 3 | BlackRockBlackRockindex-like | $18.2M | 7.82% | +195.59% | |
| 4 | Two Sigma InvestmentsTwo Sigma | $14.7M | 6.30% | +2.31% | |
| 5 | Vanguard Capital ManagementVanguardindex-like | $13.8M | 5.91% | +22.72% | |
| 6 | Acadian Asset ManagementAcadian | $13.0M | 5.59% | −5.84% | |
| 7 | Citadel AdvisorsCitadel | $11.3M | 4.87% | +33.11% | |
| 8 | Renaissance TechnologiesRenaissance Technologies | $7.8M | 3.35% | −16.98% | |
| 9 | Opaleye ManagementOpaleye | $6.9M | 2.94% | 0.00% | |
| 10 | Orbimed AdvisorsOrbimed | $6.7M | 2.90% | new | |
| 11 | Decheng CapitalDecheng Capital | $6.4M | 2.76% | 0.00% | |
| 12 | Geode Capital ManagementGeodeindex-like | $6.2M | 2.68% | +106.77% | |
| 13 | Bank of AmericaBank of America | $5.4M | 2.32% | −1.56% | |
| 14 | Ishara InvestmentsIshara | $5.0M | 2.14% | −16.67% | |
| 15 | Primecap ManagementPrimecap | $4.6M | 2.00% | 0.00% | |
| 16 | PfizerPfizer | $4.6M | 1.99% | 0.00% | |
| 17 | Soleus Capital ManagementSoleus | $4.6M | 1.98% | new | |
| 18 | State StreetState Streetindex-like | $4.3M | 1.85% | +255.41% | |
| 19 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $3.9M | 1.69% | +124.22% | |
| 20 | Connor, Clark & Lunn Investment ManagementConnor, Clark & Lunn | $3.7M | 1.58% | −4.29% | |
| 21 | Millennium ManagementMillennium | $3.2M | 1.38% | −48.50% | |
| 22 | ADAR1 Capital ManagementADAR1 | $3.2M | 1.36% | +351.31% | |
| 23 | Marshall WaceMarshall Wace | $2.9M | 1.23% | +50.64% | |
| 24 | Qube Research & TechnologiesQube Research & Technologies | $2.8M | 1.20% | −9.78% | |
| 25 | D. E. ShawD. E. Shaw | $2.7M | 1.14% | −63.17% |
114 managers report $232.7M of Zentalis Pharmaceuticals on form 13F for the quarter ended Jun 30 '26. 22 of them hold 80% of it; Squadron is largest at 8.60%.
Zentalis Pharmaceuticals, Inc.
1.94
−0.05 · −2.44%
post 1.94 +0.01%
Linked news
No implied move.
No implied move.
Expected move
No implied move.